Publicaciones en colaboración con investigadores/as de University of California, San Francisco (19)

2024

  1. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study

    Cancer, Vol. 130, Núm. 6, pp. 886-900

  2. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study

    European Journal of Haematology, Vol. 112, Núm. 3, pp. 402-411

  3. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

  4. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

    Blood Advances, Vol. 8, Núm. 1, pp. 194-206

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma

    Cancer, Vol. 129, Núm. 13, pp. 2035-2046

  3. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 12, pp. 811-818

2022

  1. Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)

    Microbiology Spectrum, Vol. 10, Núm. 3

  2. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2021

  1. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit

    Schizophrenia Research, Vol. 227, pp. 10-17

  2. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

    New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802

2020

  1. Transcatheter Treatment of Residual Significant Mitral Regurgitation Following TAVR: A Multicenter Registry

    JACC: Cardiovascular Interventions, Vol. 13, Núm. 23, pp. 2782-2791

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. A global reference for human genetic variation

    Nature, Vol. 526, Núm. 7571, pp. 68-74

2014

  1. Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel

    Nature Communications, Vol. 5

2012

  1. An integrated map of genetic variation from 1,092 human genomes

    Nature, Vol. 491, Núm. 7422, pp. 56-65

2008

  1. Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease

    Catheterization and Cardiovascular Interventions, Vol. 72, Núm. 1, pp. 116-120

  2. Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome

    Journal of Thrombosis and Thrombolysis, Vol. 25, Núm. 2, pp. 214-218

2002

  1. Validity of self-reporting of episodes of external genital warts

    Clinical Infectious Diseases, Vol. 35, Núm. 1, pp. 39-45